JERUSALEM, July 12, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will deliver a presentation titled, "Oral Insulin for Diabetes Treatment: [...]
JERUSALEM, July 11, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has agreed to schedule an End-of-Phase II meeting with Oramed [...]
JERUSALEM, July 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received approval from the Israel Securities Authority to dual-list its common stock on the Tel [...]
JERUSALEM, June 27, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property Office has publicized its intent to grant Oramed a patent titled, "Methods and [...]
JERUSALEM, June 6, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing the recent Phase IIb study of its orally ingestible insulin capsule, ORMD-0801, will be presented [...]
JERUSALEM, May 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer, Nadav Kidron, will present at three conferences next week in Tel Aviv, Israel. Oppenheimer's 17th [...]
JERUSALEM, May 9, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed a patent titled, "Methods and Compositions for Oral Administration of [...]
JERUSALEM, May 2, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that based on positive preclinical data, the Company is developing a new drug candidate, a weight loss treatment [...]
JERUSALEM, April 20, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has granted the Company a patent titled, "Methods and Compositions for Treating Diabetes: [...]
JERUSALEM, April 4, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today a new paper co-authored by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, and Dr. Ehud Arbit. The paper, [...]